
Despite being a market leader in insulin pen needles and syringes, Embecta Corp (NASDAQ:EMBC) may face challenges ahead, since the markets are already mature and the company has not diversified, according to BofA Securities.
The Embecta Analyst: Travis Steed initiated coverage of Embecta with an Underperform rating and a price target of $25.